Dr. Koch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
25 Courtenay Dr
Charleston, SC 29425Phone+1 843-792-6982
Education & Training
- Medical University of South CarolinaFellowship, Gastroenterology, 2004 - 2007
- University of Alabama Medical CenterResidency, Internal Medicine, 2001 - 2004
- Louisiana State University School of Medicine in New OrleansClass of 2001
Certifications & Licensure
- ME State Medical License 2020 - 2025
- SC State Medical License 2004 - 2025
- AL State Medical License 2002 - 2004
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury Start of enrollment: 2012 Jun 01
Publications & Presentations
PubMed
- 86 citationsValidation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease.Scott H. Stewart, David G. Koch, Ira Willner, Raymond F. Anton, Adrian Reuben
Alcoholism, Clinical and Experimental Research. 2014-05-21 - 469 citationsDrug-induced acute liver failure: results of a U.S. multicenter, prospective study.Adrian Reuben, David G. Koch, William M. Lee
Hepatology. 2010-12-01 - 82 citationsDevelopment of a Model to Predict Transplant-free Survival of Patients With Acute Liver Failure.David G. Koch, Holly Tillman, Valerie Durkalski, William M. Lee, Adrian Reuben
Clinical Gastroenterology and Hepatology. 2016-08-01
Journal Articles
- Use of Intra‐Aortic Counterpulsation in Cardiogenic Shock Post‐Liver TransplantationGabriel R Chedister, William D Stoll, Kenneth D Chavin, John W McGillicuddy, Satish N Nadig, David G Koch, Clinical Transplantation
Press Mentions
- First Edition: April 23, 2020April 23rd, 2020
Grant Support
- Novel Mechanisms of Hepatopulmonary SyndromeNIH/NHLBI2018–2024
- TARGET-HCC: A Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular CarcinomaTARGET-RWE2016–2024
- TARGET-NASH: A 5-year, Longitudinal, Observational Study of Patients with Nonalcoholic Fatty Liver Disease or Nonalcoholic SteatohepatitisTARGET-RWE2016–2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: